One major drawback of siRNA-based therapies is that they lack sufficient in-vivo delivery of siRNA into the target cells because of the large size and negative charge density of siRNA. Efficient transfer of siRNA to the liver has been achieved by lipid nanoparticles, polymer conjugates, and peptide conjugates. One of the major challenges of current methods of transfer is the nonbiodegradability of the vessel once it is inside the body.